Lupus Nephritis Treatment Market Report and Forecast 2025-2034

The lupus nephritis treatment market size was valued at USD 1.80 Billion in 2024, driven by the emphasis on preventing kidney failures. The market is expected to grow at a CAGR of 7.50% during the forecast period of 2025-2034, with the values likely to reach USD 3.71 Billion by 2034.

Lupus Nephritis Treatment: Introduction

Lupus is an autoimmune disease wherein the immune system starts attacking the healthy cells of the body. Lupus nephritis is the specific targeting and damage to the kidneys. Proliferative nephritis is the most severe kind of nephritis that may even cause permanent damage to the kidneys. Lupus nephritis treatment includes the administration of corticosteroids, immunosuppressants, blood pressure medications and diuretics. Dietary changes like reduced sodium intake and lesser consumption of protein are also advised as a part of the treatment.

Lupus Nephritis Treatment Market Analysis

Lupus nephritis treatment has observed significant evolution in recent years. B cells play a pivotal role in the pathogenesis of lupus nephritis. Hence, major areas of action in any medication revolve around either B-cell depletion or anti-B-cell activation. Currently, Rituximab is a commonly used medication for lupus nephritis treatment. Numerous medications are also under clinical trials, which are further expected to fuel the lupus nephritis treatment market growth.

Lupus nephritis may lead to chronic kidney failure diseases and is also associated with high blood pressure. Voclosporin (Lupkynis™) has been found safe and effective in treating the disease. It is a structurally modified calcineurin inhibitor, which acts as an immunosuppressant as well as promotes podocyte stability in the kidney. It also led to continuous improvement in proteinuria (presence of protein urine), which is another major symptom of lupus nephritis.

In June 2023, Kyverna Therapeutics, a United States based cell therapy company, received the FDA approval for KYV-101, designed to treat refractory lupus nephritis. The medication works on a novel anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy which depletes B cells, including autoreactive B cells, present in patients with this autoimmune disease. With the advent of new therapies and latest advancements, the lupus nephritis treatment market demand is expected to rise more in the upcoming years.

Lupus Nephritis Treatment Market Segmentation

“Lupus Nephritis Treatment Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class

• NSAIDs
• Corticosteroids
• Immunosuppressants
• Others

Market Breakup by Treatment Type

• Medication
• Dialysis
• Kidney Transplant

Market Breakup by Route of Administration

• Oral
• Parenteral
• Others

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Market Breakup by End User

• Hospitals and Clinics
• Research and Academic Laboratories
• Others

Market Breakup by Region

• United States
• United Kingdom
• Germany
• France
• Italy
• Spain
• Japan

Lupus Nephritis Treatment Market Overview

The growing convergence of technology into the medical ecosystem has paved the way for artificial intelligence and machine learning enabled diagnosis. The United States, having a robust medical and technical infrastructure, is anticipated to pioneer the lupus nephritis treatment market share in the forecast period. The researchers from University of Houston have also received a USD 3 million grant to offer rapid and precise diagnosis of the disease.

Europe is another major market for lupus nephritis treatment. With a prominent healthcare scenario for the geriatric population, it is home to several leading research and academic institutions working on offering effective treatment options to a wide set of audiences present in the region.

The Asia Pacific region is expected to witness a rapid surge in the lupus nephritis treatment market value, attributed to high investment in building medical infrastructure. There is also an influx of foreign capital, especially from leading medical companies. Government initiatives to spread relevant awareness are also on the rise. Lupus Awareness Month organized every October in Australia is a prime example. This program is aimed at delivering awareness of disease to offer early diagnosis and improve treatment.

Lupus Nephritis Treatment Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• F. Hoffmann-La Roche Ltd
• AstraZeneca
• Aurinia Pharmaceuticals Inc.
• GlaxoSmithKline plc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Vertice Pharma
• Bayer AG
• Sanofi
• Sumitomo Corporation
• LEO Pharma A/S
• Cipla Inc.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.